Interleukin-2, interferon-α and medroxyprogesterone acetate in metastatic renal cell carcinoma

Emanuele Naglieri, Massimo Lopez, Giorgio Lelli, Francesco Morelli, Antonella Amodio, Pasquale di Tonno, Nicola Gebbia, Marisa Di Seri, Maria Concetta Chetri, Pietro Rizzo, Ines Abbate, Addolorata Casamassima, Francesco Paolo Selvaggi, Giuseppe Colucci

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Interleukin-2 (IL-2) and interferon-α (IFN-α) are the main immuno-biological agents used in the therapy of metastatic renal cell carcinoma (RCC). Unfortunately the promising results obtained in biological studies have not yet been confirmed in clinical studies. One reason is linked to the immunosuppression of metastatic patients which is caused by macrophage products. IL-6 in particular is considered a growth factor for RCC. Medroxyprogesterone acetate (MPA) may interfere with IL-6 macrophage production, possibly causing a synergistic effect in association with IL-2 and IFN-α. Therefore the purpose of our study was to evaluate the toxicity and the efficacy of the association between IL-2, IFN-α and MPA. Patients and Methods: Forty-two consecutive patients with metastatic RCC were enrolled. IL-2 was administered subcutaneously at doses of 4.5 million UI on days 1-5, 8-12, 15-19 and 22-26; IFN-α was administered s.c. at a dose of 3 million t.t.w; MPA was administered orally at a dose of 1000 mg daily. This schedule was repeated after a rest of 2 weeks. Results: Toxicity was mild: the main symptoms observed were fatigue and fever. Six CR (14%), five PR (12%), thirteen SD (31%) and seventeen PD (41%) were observed for an overall response rate of 26%. Patients with good PS and low levels of CRP had a better prognosis. Conclusion: Considering both the good activity and the low toxicity of this scheme, we think that it could be carried out in normal clinical practice.

Original languageEnglish
Pages (from-to)3045-3052
Number of pages8
JournalAnticancer Research
Volume22
Issue number5
Publication statusPublished - Sep 2002

Fingerprint

Medroxyprogesterone Acetate
Renal Cell Carcinoma
Interferons
Interleukin-2
Interleukin-6
Macrophages
Biological Factors
Immunosuppression
Fatigue
Intercellular Signaling Peptides and Proteins
Appointments and Schedules
Fever
Therapeutics

Keywords

  • C-reactive protein
  • Immunotherapy
  • Interleukin-2
  • Interleukin-6
  • Medroxyprogesterone acetate
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Naglieri, E., Lopez, M., Lelli, G., Morelli, F., Amodio, A., di Tonno, P., ... Colucci, G. (2002). Interleukin-2, interferon-α and medroxyprogesterone acetate in metastatic renal cell carcinoma. Anticancer Research, 22(5), 3045-3052.

Interleukin-2, interferon-α and medroxyprogesterone acetate in metastatic renal cell carcinoma. / Naglieri, Emanuele; Lopez, Massimo; Lelli, Giorgio; Morelli, Francesco; Amodio, Antonella; di Tonno, Pasquale; Gebbia, Nicola; Di Seri, Marisa; Concetta Chetri, Maria; Rizzo, Pietro; Abbate, Ines; Casamassima, Addolorata; Paolo Selvaggi, Francesco; Colucci, Giuseppe.

In: Anticancer Research, Vol. 22, No. 5, 09.2002, p. 3045-3052.

Research output: Contribution to journalArticle

Naglieri, E, Lopez, M, Lelli, G, Morelli, F, Amodio, A, di Tonno, P, Gebbia, N, Di Seri, M, Concetta Chetri, M, Rizzo, P, Abbate, I, Casamassima, A, Paolo Selvaggi, F & Colucci, G 2002, 'Interleukin-2, interferon-α and medroxyprogesterone acetate in metastatic renal cell carcinoma', Anticancer Research, vol. 22, no. 5, pp. 3045-3052.
Naglieri E, Lopez M, Lelli G, Morelli F, Amodio A, di Tonno P et al. Interleukin-2, interferon-α and medroxyprogesterone acetate in metastatic renal cell carcinoma. Anticancer Research. 2002 Sep;22(5):3045-3052.
Naglieri, Emanuele ; Lopez, Massimo ; Lelli, Giorgio ; Morelli, Francesco ; Amodio, Antonella ; di Tonno, Pasquale ; Gebbia, Nicola ; Di Seri, Marisa ; Concetta Chetri, Maria ; Rizzo, Pietro ; Abbate, Ines ; Casamassima, Addolorata ; Paolo Selvaggi, Francesco ; Colucci, Giuseppe. / Interleukin-2, interferon-α and medroxyprogesterone acetate in metastatic renal cell carcinoma. In: Anticancer Research. 2002 ; Vol. 22, No. 5. pp. 3045-3052.
@article{d57ef3a2c64f4b2fb5f84f818eedf0ef,
title = "Interleukin-2, interferon-α and medroxyprogesterone acetate in metastatic renal cell carcinoma",
abstract = "Background: Interleukin-2 (IL-2) and interferon-α (IFN-α) are the main immuno-biological agents used in the therapy of metastatic renal cell carcinoma (RCC). Unfortunately the promising results obtained in biological studies have not yet been confirmed in clinical studies. One reason is linked to the immunosuppression of metastatic patients which is caused by macrophage products. IL-6 in particular is considered a growth factor for RCC. Medroxyprogesterone acetate (MPA) may interfere with IL-6 macrophage production, possibly causing a synergistic effect in association with IL-2 and IFN-α. Therefore the purpose of our study was to evaluate the toxicity and the efficacy of the association between IL-2, IFN-α and MPA. Patients and Methods: Forty-two consecutive patients with metastatic RCC were enrolled. IL-2 was administered subcutaneously at doses of 4.5 million UI on days 1-5, 8-12, 15-19 and 22-26; IFN-α was administered s.c. at a dose of 3 million t.t.w; MPA was administered orally at a dose of 1000 mg daily. This schedule was repeated after a rest of 2 weeks. Results: Toxicity was mild: the main symptoms observed were fatigue and fever. Six CR (14{\%}), five PR (12{\%}), thirteen SD (31{\%}) and seventeen PD (41{\%}) were observed for an overall response rate of 26{\%}. Patients with good PS and low levels of CRP had a better prognosis. Conclusion: Considering both the good activity and the low toxicity of this scheme, we think that it could be carried out in normal clinical practice.",
keywords = "C-reactive protein, Immunotherapy, Interleukin-2, Interleukin-6, Medroxyprogesterone acetate, Renal cell carcinoma",
author = "Emanuele Naglieri and Massimo Lopez and Giorgio Lelli and Francesco Morelli and Antonella Amodio and {di Tonno}, Pasquale and Nicola Gebbia and {Di Seri}, Marisa and {Concetta Chetri}, Maria and Pietro Rizzo and Ines Abbate and Addolorata Casamassima and {Paolo Selvaggi}, Francesco and Giuseppe Colucci",
year = "2002",
month = "9",
language = "English",
volume = "22",
pages = "3045--3052",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Interleukin-2, interferon-α and medroxyprogesterone acetate in metastatic renal cell carcinoma

AU - Naglieri, Emanuele

AU - Lopez, Massimo

AU - Lelli, Giorgio

AU - Morelli, Francesco

AU - Amodio, Antonella

AU - di Tonno, Pasquale

AU - Gebbia, Nicola

AU - Di Seri, Marisa

AU - Concetta Chetri, Maria

AU - Rizzo, Pietro

AU - Abbate, Ines

AU - Casamassima, Addolorata

AU - Paolo Selvaggi, Francesco

AU - Colucci, Giuseppe

PY - 2002/9

Y1 - 2002/9

N2 - Background: Interleukin-2 (IL-2) and interferon-α (IFN-α) are the main immuno-biological agents used in the therapy of metastatic renal cell carcinoma (RCC). Unfortunately the promising results obtained in biological studies have not yet been confirmed in clinical studies. One reason is linked to the immunosuppression of metastatic patients which is caused by macrophage products. IL-6 in particular is considered a growth factor for RCC. Medroxyprogesterone acetate (MPA) may interfere with IL-6 macrophage production, possibly causing a synergistic effect in association with IL-2 and IFN-α. Therefore the purpose of our study was to evaluate the toxicity and the efficacy of the association between IL-2, IFN-α and MPA. Patients and Methods: Forty-two consecutive patients with metastatic RCC were enrolled. IL-2 was administered subcutaneously at doses of 4.5 million UI on days 1-5, 8-12, 15-19 and 22-26; IFN-α was administered s.c. at a dose of 3 million t.t.w; MPA was administered orally at a dose of 1000 mg daily. This schedule was repeated after a rest of 2 weeks. Results: Toxicity was mild: the main symptoms observed were fatigue and fever. Six CR (14%), five PR (12%), thirteen SD (31%) and seventeen PD (41%) were observed for an overall response rate of 26%. Patients with good PS and low levels of CRP had a better prognosis. Conclusion: Considering both the good activity and the low toxicity of this scheme, we think that it could be carried out in normal clinical practice.

AB - Background: Interleukin-2 (IL-2) and interferon-α (IFN-α) are the main immuno-biological agents used in the therapy of metastatic renal cell carcinoma (RCC). Unfortunately the promising results obtained in biological studies have not yet been confirmed in clinical studies. One reason is linked to the immunosuppression of metastatic patients which is caused by macrophage products. IL-6 in particular is considered a growth factor for RCC. Medroxyprogesterone acetate (MPA) may interfere with IL-6 macrophage production, possibly causing a synergistic effect in association with IL-2 and IFN-α. Therefore the purpose of our study was to evaluate the toxicity and the efficacy of the association between IL-2, IFN-α and MPA. Patients and Methods: Forty-two consecutive patients with metastatic RCC were enrolled. IL-2 was administered subcutaneously at doses of 4.5 million UI on days 1-5, 8-12, 15-19 and 22-26; IFN-α was administered s.c. at a dose of 3 million t.t.w; MPA was administered orally at a dose of 1000 mg daily. This schedule was repeated after a rest of 2 weeks. Results: Toxicity was mild: the main symptoms observed were fatigue and fever. Six CR (14%), five PR (12%), thirteen SD (31%) and seventeen PD (41%) were observed for an overall response rate of 26%. Patients with good PS and low levels of CRP had a better prognosis. Conclusion: Considering both the good activity and the low toxicity of this scheme, we think that it could be carried out in normal clinical practice.

KW - C-reactive protein

KW - Immunotherapy

KW - Interleukin-2

KW - Interleukin-6

KW - Medroxyprogesterone acetate

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0036765649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036765649&partnerID=8YFLogxK

M3 - Article

C2 - 12530040

AN - SCOPUS:0036765649

VL - 22

SP - 3045

EP - 3052

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -